{
  "id": 5067,
  "text": "J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.\n\n<question>: ",
  "ChatGPT_response_0": "根据《J Clin Oncol》期刊上的研究，tisotumab vedotin在治疗之前接受过治疗的复发或转移性宫颈癌患者中显示了一定的疗效和安全性。这项研究展示了tisotumab vedotin在这类患者中的潜在治疗作用，为进一步研究和临床应用提供了有益信息。针对该疗法的具体疗效和安全性情况，建议您咨询专业医务人员以获取更详尽的信息。",
  "query": "在之前治疗过的复发或转移性宫颈癌患者中，tisotumab vedotin的疗效和安全性如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在之前治疗过的复发或转移性宫颈癌患者中，tisotumab vedotin的疗效和安全性如何？\n\n<reference text>: J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.\n\n<reply>: ",
  "response": "根据《J Clin Oncol》期刊上的研究，tisotumab vedotin在治疗之前接受过治疗的复发或转移性宫颈癌患者中显示了一定的疗效和安全性。这项研究展示了tisotumab vedotin在这类患者中的潜在治疗作用，为进一步研究和临床应用提供了有益信息。针对该疗法的具体疗效和安全性情况，建议您咨询专业医务人员以获取更详尽的信息。"
}